

References

I-240

1. Zynlonta (loncastuximab tesirine-lpyl.), injection, for intravenous use [package insert]. ADC Therapeutics. Murray Hill, HJ. 2021. Revised 10/2022.
2. Clinical Pharmacology™ 2024. Tampa FL: Gold Standard, Inc. Loncastuximab tesirine-lpyl.
3. Micromedex DrugDex Compendium®. 2024. Loncastuximab tesirine-lpyl.
4. National Comprehensive Cancer Network (NCCN). Loncastuximab tesirine-lpyl. NCCN Drugs and Biologics Compendium®. 2024.
5. Loncastuximab tesirine-lpyl In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated December 13, 2021.
6. Caimi PF, Ai W, Alderuccio JP, et al. Locastuximab tesirine in relapsed or refractory large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. *Lancet Oncol*. 2021;22(6):790-800.